[1]Le Moli R, Malandrino P, Russo M, et al. Corticosteroid Pulse Therapy for Graves’ Ophthalmopathy Reduces the Relapse Rate of Graves’ Hyperthyroidism[J]. Front Endocrinol (Lausanne), 2020,11:367.
[2] Chung J H. Antithyroid Drug Treatment in Graves’ Disease[J]. Endocrinol Metab (Seoul), 2021,36(3):491-499.
[4]Jiang X, Hu H, Fu Z, et al. ASSOCIATION BETWEEN THE CTLA-4 EXON 1+49A/G POLYMORPHISM AND THE RELAPSE OF GRAVE’S DISEASE AFTER ATD WITHDRAWAL: A META-ANALYSIS[J]. Acta Endocrinol(Buchar), 2022,18(3):324-332.
[5]Yao Q, Song Z, Wang B, et al. Identification of lncRNA and mRNA Expression Profile in Relapsed Graves’ Disease[J]. Front Cell Dev Biol, 2021,9:756560.
[10] Vaivode I, Zake T, Strele I, et al. Stress-Related Immune Response and Selenium Status in Autoimmune Thyroid Disease Patients[J]. Int J Mol Sci, 2023,24(3).
[13]Gorini F, Sabatino L, Pingitore A, et al. Selenium: An Element of Life Essential for Thyroid Function[J]. Molecules, 2021,26(23).
[14]Cho Y Y, Chung Y J. Vitamin D supplementation does not prevent the recurrence of Graves’ disease[J]. Sci Rep, 2020,10(1):16.
[15] 夏秦 . 儿童 Graves 病的血清非靶向代谢组学研究[D]. 苏州大学 ,2021.
[16]Bostan H, Ucan B, Kizilgul M, et al. Relapsed and newly diagnosed Graves’ disease due to immunization against COVID-19: A case series and review of the literature[J]. J Autoimmun, 2022,128:102809.
[17]Cao J, Wang N, Luo Y, et al. A cause-effect relationship between Graves’ disease and the gut microbiome contributes to the thyroid-gut axis: A bidirectional two-sample Mendelian randomization study[J]. Front Immunol, 2023,14:977587.
